Calgary, Alberta – March 25, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum...
Calgary, Alberta – March 18, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum...
Calgary, Alberta – March 4, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a biotechnology company developing novel therapies for neurological and...
Calgary, Alberta, Canada – Wednesday, February 18, 2026 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 50,001 deferred share units...
Calgary, Alberta – Wednesday, February 18, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), is pleased to announce that it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC...
Calgary, Alberta – February 3, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel therapeutics for autism spectrum...
